313 related articles for article (PubMed ID: 35106794)
1. Tumor-derived exosomes induce immunosuppressive macrophages to foster intrahepatic cholangiocarcinoma progression.
Luo C; Xin H; Zhou Z; Hu Z; Sun R; Yao N; Sun Q; Borjigin U; Wu X; Fan J; Huang X; Zhou S; Zhou J
Hepatology; 2022 Oct; 76(4):982-999. PubMed ID: 35106794
[TBL] [Abstract][Full Text] [Related]
2. Reactive oxygen species reprogram macrophages to suppress antitumor immune response through the exosomal miR-155-5p/PD-L1 pathway.
Li X; Wang S; Mu W; Barry J; Han A; Carpenter RL; Jiang BH; Peiper SC; Mahoney MG; Aplin AE; Ren H; He J
J Exp Clin Cancer Res; 2022 Jan; 41(1):41. PubMed ID: 35086548
[TBL] [Abstract][Full Text] [Related]
3. Endoplasmic Reticulum Stress Causes Liver Cancer Cells to Release Exosomal miR-23a-3p and Up-regulate Programmed Death Ligand 1 Expression in Macrophages.
Liu J; Fan L; Yu H; Zhang J; He Y; Feng D; Wang F; Li X; Liu Q; Li Y; Guo Z; Gao B; Wei W; Wang H; Sun G
Hepatology; 2019 Jul; 70(1):241-258. PubMed ID: 30854665
[TBL] [Abstract][Full Text] [Related]
4. Cancer-associated fibroblasts-derived exosomes promote lung cancer progression by OIP5-AS1/ miR-142-5p/ PD-L1 axis.
Jiang Y; Wang K; Lu X; Wang Y; Chen J
Mol Immunol; 2021 Dec; 140():47-58. PubMed ID: 34653794
[TBL] [Abstract][Full Text] [Related]
5. Expression of Programmed Death Ligand 1 Is Associated with the Prognosis of Intrahepatic Cholangiocarcinoma.
Dong Z; Liao B; Shen W; Sui C; Yang J
Dig Dis Sci; 2020 Feb; 65(2):480-488. PubMed ID: 31410753
[TBL] [Abstract][Full Text] [Related]
6. Serum exosomal miR-16-5p functions as a tumor inhibitor and a new biomarker for PD-L1 inhibitor-dependent immunotherapy in lung adenocarcinoma by regulating PD-L1 expression.
Chen HL; Luo YP; Lin MW; Peng XX; Liu ML; Wang YC; Li SJ; Yang DH; Yang ZX
Cancer Med; 2022 Jul; 11(13):2627-2643. PubMed ID: 35347894
[TBL] [Abstract][Full Text] [Related]
7. M
Qiu X; Yang S; Wang S; Wu J; Zheng B; Wang K; Shen S; Jeong S; Li Z; Zhu Y; Wu T; Wu X; Wu R; Liu W; Wang HY; Chen L
Cancer Res; 2021 Sep; 81(18):4778-4793. PubMed ID: 34301762
[TBL] [Abstract][Full Text] [Related]
8. N6-methyladenosine-modified circSLCO1B3 promotes intrahepatic cholangiocarcinoma progression via regulating HOXC8 and PD-L1.
Li J; Xu X; Xu K; Zhou X; Wu K; Yao Y; Liu Z; Chen C; Wang L; Sun Z; Jiao D; Han X
J Exp Clin Cancer Res; 2024 Apr; 43(1):119. PubMed ID: 38641828
[TBL] [Abstract][Full Text] [Related]
9. Cancer-associated fibroblasts promote tumor cell growth via miR-493-5p in intrahepatic cholangiocarcinoma.
Toshida K; Itoh S; Harada N; Morinaga A; Yugawa K; Tomiyama T; Kosai-Fujimoto Y; Tomino T; Kurihara T; Nagao Y; Morita K; Oda Y; Yoshizumi T
Cancer Sci; 2023 Mar; 114(3):937-947. PubMed ID: 36369960
[TBL] [Abstract][Full Text] [Related]
10. Exosome-derived miR-182-5p promoted cholangiocarcinoma progression and vasculogenesis by regulating ADK/SEMA5a/PI3K pathway.
Wang J; Jiang W; Liu S; Shi K; Zhang Y; Chen Y; Shan J; Wang Y; Xu X; Li C; Li X
Liver Int; 2024 Feb; 44(2):370-388. PubMed ID: 37950359
[TBL] [Abstract][Full Text] [Related]
11. Liver kinase B1 in exosomes inhibits immune checkpoint programmed death ligand 1 and metastatic progression of intrahepatic cholangiocarcinoma.
Liu Z; Zhou K; Zeng J; Zhou X; Li H; Peng K; Liu X; Li F; Jiang B; Zhao M; Ma T
Oncol Rep; 2022 Sep; 48(3):. PubMed ID: 35856436
[TBL] [Abstract][Full Text] [Related]
12. Immune cell atlas of cholangiocarcinomas reveals distinct tumor microenvironments and associated prognoses.
Xia T; Li K; Niu N; Shao Y; Ding D; Thomas DL; Jing H; Fujiwara K; Hu H; Osipov A; Yuan C; Wolfgang CL; Thompson ED; Anders RA; He J; Mou Y; Murphy AG; Zheng L
J Hematol Oncol; 2022 Mar; 15(1):37. PubMed ID: 35346322
[TBL] [Abstract][Full Text] [Related]
13. Exosomal miR-30a-5p promoted intrahepatic cholangiocarcinoma progression by increasing angiogenesis and vascular permeability in PDCD10 dependent manner.
Jiang W; Shi X; Sun L; Zhang Y; Kong X; Yang X; Yin Y; Li C; Li X
Int J Biol Sci; 2023; 19(14):4571-4587. PubMed ID: 37781039
[TBL] [Abstract][Full Text] [Related]
14. CTLA-4 Synergizes With PD1/PD-L1 in the Inhibitory Tumor Microenvironment of Intrahepatic Cholangiocarcinoma.
Guo XJ; Lu JC; Zeng HY; Zhou R; Sun QM; Yang GH; Pei YZ; Meng XL; Shen YH; Zhang PF; Cai JB; Huang PX; Ke AW; Shi YH; Zhou J; Fan J; Chen Y; Yang LX; Shi GM; Huang XY
Front Immunol; 2021; 12():705378. PubMed ID: 34526987
[TBL] [Abstract][Full Text] [Related]
15. csi-miR-96-5p delivered by Clonorchis sinensis extracellular vesicles promotes intrahepatic cholangiocarcinoma proliferation and migration via the ferroptosis-related PTEN/SLC7A11/GPX4 axis.
Wen LJ; Yin JG; Wang YX; Liu K; Zhao JX
Parasit Vectors; 2023 Dec; 16(1):465. PubMed ID: 38124152
[TBL] [Abstract][Full Text] [Related]
16. Exosomal miR-222 from adriamycin-resistant MCF-7 breast cancer cells promote macrophages M2 polarization via PTEN/Akt to induce tumor progression.
Chen WX; Wang DD; Zhu B; Zhu YZ; Zheng L; Feng ZQ; Qin XH
Aging (Albany NY); 2021 Mar; 13(7):10415-10430. PubMed ID: 33752173
[TBL] [Abstract][Full Text] [Related]
17. Tumor suppressive activity of miR-424-5p in breast cancer cells through targeting PD-L1 and modulating PTEN/PI3K/AKT/mTOR signaling pathway.
Dastmalchi N; Hosseinpourfeizi MA; Khojasteh SMB; Baradaran B; Safaralizadeh R
Life Sci; 2020 Oct; 259():118239. PubMed ID: 32784058
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of programmed cell death ligand 1 expression in patients with intrahepatic cholangiocarcinoma: a meta-analysis.
Xian F; Ren D; Bie J; Xu G
Front Immunol; 2023; 14():1119168. PubMed ID: 37138876
[TBL] [Abstract][Full Text] [Related]
19. Lipotoxic Hepatocyte-Derived Exosomal MicroRNA 192-5p Activates Macrophages Through Rictor/Akt/Forkhead Box Transcription Factor O1 Signaling in Nonalcoholic Fatty Liver Disease.
Liu XL; Pan Q; Cao HX; Xin FZ; Zhao ZH; Yang RX; Zeng J; Zhou H; Fan JG
Hepatology; 2020 Aug; 72(2):454-469. PubMed ID: 31782176
[TBL] [Abstract][Full Text] [Related]
20. Program Death 1 Immune Checkpoint and Tumor Microenvironment: Implications for Patients With Intrahepatic Cholangiocarcinoma.
Gani F; Nagarajan N; Kim Y; Zhu Q; Luan L; Bhaijjee F; Anders RA; Pawlik TM
Ann Surg Oncol; 2016 Aug; 23(8):2610-7. PubMed ID: 27012989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
